Recently targeted kinases and their inhibitors - the path to clinical trials

Recently targeted kinases and their inhibitors - the path to clinical trials

Show other versions (1)

Bibliographic Details
Main Authors:	Knapp, S, Sundstrom, M
Format:	Journal article
Published:	2014

Similar Items

Recently targeted kinases and their inhibitors-the path to clinical trials.
by: Knapp, S, et al.
Published: (2014)

Insights for the development of specific kinase inhibitors by targeted structural genomics.
by: Fedorov, O, et al.
Published: (2007)

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
by: Fedorov, O, et al.
Published: (2007)

Targeting kinases for the treatment of inflammatory diseases.
by: Müller, S, et al.
Published: (2010)

Kinase inhibitor selectivity profiling using differential scanning fluorimetry.
by: Fedorov, O, et al.
Published: (2012)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
by: Ahn, Ryuhjin, et al.
Published: (2021)

Development of bioreductive inhibitors of checkpoint kinase 1 to target hypoxic tumours
by: Körner, C
Published: (2015)

High-throughput structural characterisation of therapeutic protein targets.
by: Marsden, B, et al.
Published: (2006)

High-throughput structural characterisation of therapeutic protein targets
by: Marsden, B, et al.
Published: (2006)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
by: Akué-Gédu, R, et al.
Published: (2009)

A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
by: Taylor, M, et al.
Published: (2017)

Discovery of BET bromodomain inhibitors and their role in target validation
by: Mueller, S, et al.
Published: (2014)

The cysteinome of protein kinases as a target in drug development
by: Chaikuad, A, et al.
Published: (2018)

Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens
by: Beeharry, Neil, et al.
Published: (2018)

Versatile selective kinase inhibitors: Chemistry and biology of indirubins
by: Gaboriaud-Kolar, N, et al.
Published: (2012)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
by: Ciceri, P, et al.
Published: (2014)

Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.
by: Cowan-Jacob, S, et al.
Published: (2014)

Functional characterization of the cyclin-dependent kinase inhibitor p21 by gene targeting in the mouse
by: Brugarolas, James (James Burfau), 1969-
Published: (2009)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
by: Bullock, A, et al.
Published: (2009)

DFG-1 residue controls inhibitor binding mode and affinity, providing a basis for rational design of kinase inhibitor selectivity
by: Schröder, M, et al.
Published: (2020)

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.
by: Hellwig, S, et al.
Published: (2012)

Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
by: Ekambaram, R, et al.
Published: (2013)

Polynucleotide kinase as a potential target for enhancing cytotoxicity by ionizing radiation and topoisomerase I inhibitors.
by: Bernstein, N, et al.
Published: (2008)

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
by: Bataille, C, et al.
Published: (2017)

Identification and characterization of a small-molecule inhibitor of death-associated protein kinase 1.
by: Wilbek, T, et al.
Published: (2015)

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
by: Miduturu, C, et al.
Published: (2011)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
by: Ciceri, P, et al.
Published: (2014)

Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
by: Taipale, Mikko, et al.
Published: (2014)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors
by: Canning, P, et al.
Published: (2015)

KOPI: kinase inhibitor proteome impact analysis
by: Li, Ginny Xiaohe, et al.
Published: (2023)

Multiplex imaging and cellular target identification of kinase inhibitors via an affinity-based proteome profiling approach
by: Su, Ying, et al.
Published: (2015)

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors
by: Suebsuwong, C, et al.
Published: (2018)

Cinnamomum iners as Mitogen-Activated Protein Kinase Kinase (MKK1) inhibitor
by: Pang, Kam Lee, et al.
Published: (2009)

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype
by: Walter, A, et al.
Published: (2018)

Recent progress in histone demethylase inhibitors
by: McAllister, T, et al.
Published: (2016)

A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination
by: Rudolf, A, et al.
Published: (2014)

Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors.
by: Feng, L, et al.
Published: (2011)

Targeting tyrosine-kinases in ovarian cancer.
by: Morotti, M, et al.
Published: (2013)

Targeting the water network in cyclin G-associated kinase (GAK) with 4-anilino-quin(az)oline inhibitors
by: Asquith, CRM, et al.
Published: (2020)